NCT02973997 2025-08-29Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)Academic and Community Cancer Research UnitedPhase 2 Completed57 enrolled 14 charts
NCT01811212 2018-04-03Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid CancerNational Cancer Institute (NCI)Phase 2 Completed25 enrolled 11 charts
NCT00121628 2013-10-09A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid CancerAmgenPhase 2 Completed184 enrolled